Cumberland PharmaceuticalsCPIX +12.50%32 PB Ratio is 4.67 as of Jun. 27, 2026, which is 289% above its 10-year median of 1.20. GuruFocus rates CPIX with a GF Score™ of 32/100 and a GF Value™ of $2.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Cumberland Pharmaceuticals ranks worse than 78.63% on this metric.
Cumberland Pharmaceuticals Inc stock PB Ratio (=4.67) is close to 10-year high of 4.67.
The historical rank and industry rank for Cumberland Pharmaceuticals's PB Ratio or its related term are showing as below:
CPIX'
s PB Ratio Range Over the Past 10 Years
Min: 0.57 Med: 1.2 Max: 4.67
Current: 4.67
During the past 13 years, Cumberland Pharmaceuticals's highest PB Ratio was 4.67. The lowest was 0.57. And the median was 1.20.
CPIX's PB Ratio is ranked worse than 78.63% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs CPIX: 4.67
During the past 12 months, Cumberland Pharmaceuticals's average Book Value Per Share Growth Rate was -24.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -13.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -13.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -10.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cumberland Pharmaceuticals was 94.00% per year. The lowest was -17.40% per year. And the median was -1.85% per year.
Back to Basics: PB Ratio
Cumberland Pharmaceuticals (NAS:CPIX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cumberland Pharmaceuticals PB Ratio Related Terms
Cumberland Pharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cumberland Pharmaceuticals (CPIX) has a PB Ratio of 4.67 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cumberland Pharmaceuticals and its competitors. This is 289% above median its historical median of 1.20. Over the past decade, Cumberland Pharmaceuticals' PB Ratio has ranged from 0.57 to 4.67. According to the industry distribution chart, Cumberland Pharmaceuticals ranks #725 out of 922 companies in the Drug Manufacturers industry, placing it in the top 78.6%.
Is Cumberland Pharmaceuticals' PB Ratio too high?
Cumberland Pharmaceuticals' current PB Ratio of 4.67 is 289% above median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 4.67. The Drug Manufacturers industry median PB Ratio is 1.83. Cumberland Pharmaceuticals' value of 4.67 is 155.9% above this industry median. Based on the distribution chart, Cumberland Pharmaceuticals ranks #725 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cumberland Pharmaceuticals has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' PB Ratio compare to CTOR and INCR?
According to the Drug Manufacturers industry distribution chart, Cumberland Pharmaceuticals ranks #725 out of 922 companies for PB Ratio. This places Cumberland Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.83. Cumberland Pharmaceuticals' value of 4.67 is 155.9% above this benchmark. Historically, Cumberland Pharmaceuticals' own PB Ratio has ranged from 0.57 to 4.67 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 1.83, Cumberland Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cumberland Pharmaceuticals's current PB Ratio of 4.67 is 155.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cumberland Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cumberland Pharmaceuticals's current PB Ratio is 4.67, which is 289% above median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $6.75 — trading 212.5% above its estimated fair value. The current PB Ratio is 4.67, which is 289% above median its 10-year median of 1.20 and 155.9% above the Drug Manufacturers industry median of 1.83. Cumberland Pharmaceuticals' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current PB Ratio is 4.67 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued.
The current stock price of $6.75 is trading 212.5% above its estimated GF Value™ of $2.16.
GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CPIX:
PB Ratio: 4.67 (289% above median its 10-year median of 1.20)
GF Value™: $2.16 vs. price of $6.75 (212.5% above fair value)
Industry Position: 155.9% above the Drug Manufacturers median (#725 of 922)
No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
32GF Score
Get the complete analysis for CPIX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPIX has been successfully added to your 
